Silexion Therapeutics Regains Nasdaq Compliance
Silexion Therapeutics Corp. (NASDAQ: SLXN) has announced a significant achievement. The company has regained compliance with the Nasdaq listing requirements, a crucial milestone for its future as a biotechnology innovator.
Understanding the Nasdaq Compliance Achievement
The Nasdaq Stock Market has provided Silexion with written notification confirming compliance with essential listing rules. These rules pertain to the minimum bid price and shareholders' equity requirements, which are vital for maintaining its stock exchange listing. This news highlights Silexion's efforts towards maintaining a credible presence in the market.
Details of Compliance
According to the notification, Silexion has successfully met the minimum bid price requirement of $1.00 per share, along with achieving the shareholders' equity requirement of $2.5 million. This is a positive turn that enables the company to continue its listing on the Nasdaq Capital Market.
CEO's Statement
Silexion's CEO, Ilan Hadar, expressed satisfaction with this compliance achievement, stating that it reinforces the company’s strong financial foundation. He emphasized the proactive steps Silexion is taking as it gears up for its planned Phase 2/3 clinical trials for SIL204, an innovative RNA interference therapy aimed at targeting KRAS-driven cancers.
Exciting Potential of SIL204
SIL204 has shown impressive preclinical data, indicating up to a 97% inhibition rate in various KRAS-driven cancer types. The anticipation is high as Silexion pushes forward with its clinical development strategy, soon to get underway in the first half of the following year.
About Silexion Therapeutics
Silexion Therapeutics is dedicated to pioneering innovative therapies aimed at treating solid tumor cancers primarily driven by the mutated KRAS oncogene. These cancers are notoriously difficult to treat, making Silexion's work critically important. The company’s earlier Phase 2a clinical trial results demonstrated a positive trend against traditional chemotherapy options, affirming its commitment to advancing oncology treatments.
Looking Ahead in Therapy Development
As Silexion continues to develop its lead product candidate, particularly focusing on locally advanced pancreatic cancer, it remains driven by a vision to improve outcomes for patients facing severe treatment challenges.
Company Contact Information
For further inquiries, Silexion Therapeutics can be reached through their CFO, Ms. Mirit Horenshtein Hadar, via email at mirit@silexion.com. Additionally, for investor relations, you can contact Arx Investor Relations at silexion@arxhq.com.
Frequently Asked Questions
What is the significance of Silexion regaining Nasdaq compliance?
This compliance is crucial for Silexion's ability to continue its public listing and attract further investment to support its clinical initiatives.
What does SIL204 target?
SIL204 is designed to target KRAS-driven cancers, offering hope for better treatment options in this challenging area of oncology.
When are Silexion's clinical trials for SIL204 expected to start?
The planned Phase 2/3 clinical trials for SIL204 are slated to begin in the first half of the next year.
What were the company’s previous trial outcomes?
Silexion's earlier trials indicated a positive trend in efficacy compared to chemotherapy alone, suggesting the potential for significant advancements in cancer treatment.
Who is Silexion Therapeutics aiming to help?
The company focuses on patients with solid tumor cancers related to the KRAS oncogene, aiming to provide new therapeutic options for those facing unmanageable conditions.
